Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)

NCT06569680 is registered in ClinicalTrials.gov with Izidore Lossos, MD as lead sponsor.

NCT NCT06569680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06569680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)
Lead sponsor
Izidore Lossos, MD
Phase
Phase 2
Overall status
Recruiting
Start date
November 19, 2024
Completion date
December 1, 2030
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal marginal zone lymphoma